Good morning. I’m feeling jealous of my colleagues who get to enjoy some good weather today in San Francisco for our Breakthrough West Summit.
The need-to-know this morning
Relay Therapeutics reported promising Phase 2 data of its drug zovegalisib in a group of rare diseases that cause abnormal vasculature development, sending company shares up 9% in premarket trading.
Lilly tops peers on R&D performance, report finds
Eli Lilly ranked first in not one, but two categories in a prominent analysis of drugmakers’ R&D activity.
